Women who have breast cancer remaining after preoperative chemotherapy and breast cancer surgery have a higher risk of the disease returning in the future. There is no chemotherapy that has been shown to reduce the risk of recurrence in these women.
In this study, researchers will evaluate the safety and effectiveness of giving bevacizumab and metronomic chemotherapy to women who had preoperative chemotherapy and had residual breast cancer removed with surgery. With metronomic chemotherapy, repetitive, low doses of chemotherapy drugs are given, which are designed to minimize side effects and target the endothelium, or tumor stroma, as opposed to targeting the tumor itself. The drugs used in this study will be cyclophosphamide and methotrexate given over a six-month period.
Investigators also want to determine if a diet and exercise program can lead to weight low, improved mood, decreased fatigue, and changes in blood markers associated with breast cancer. Patients will be randomly assigned to one of four groups:
- bevacizumab, metronomic chemotherapy, and dietary and exercise intervention
- bevacizumab, metronomic chemotherapy, and dietary intervention
- dietary and exercise intervention
- dietary intervention alone